These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 17329458)

  • 1. Great(er) expectations.
    Lauriello J
    Am J Psychiatry; 2007 Mar; 164(3):377-9. PubMed ID: 17329458
    [No Abstract]   [Full Text] [Related]  

  • 2. Cognitive improvement in response to antipsychotic drugs: neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
    Heinrichs RW
    Arch Gen Psychiatry; 2007 Jun; 64(6):631-2. PubMed ID: 17548745
    [No Abstract]   [Full Text] [Related]  

  • 3. The costs of drugs for schizophrenia.
    Freedman R; Carpenter WT; Davis JM; Goldman HH; Tamminga CA; Thomas M
    Am J Psychiatry; 2006 Dec; 163(12):2029-31. PubMed ID: 17151146
    [No Abstract]   [Full Text] [Related]  

  • 4. Pretrial medication bias in randomized antipsychotic drug trials.
    Leucht S; Heres S; Hamann J; Kissling W
    Am J Psychiatry; 2007 Aug; 164(8):1266; author reply 1266-7. PubMed ID: 17671291
    [No Abstract]   [Full Text] [Related]  

  • 5. Lessons from each drug trial.
    Marder SR
    Am J Psychiatry; 2007 Mar; 164(3):375-6. PubMed ID: 17329457
    [No Abstract]   [Full Text] [Related]  

  • 6. Switch or stay?
    Davis JM; Marder SR; Tamminga CA
    Am J Psychiatry; 2006 Dec; 163(12):2032-3. PubMed ID: 17151147
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical trials during the prodromal stage of schizophrenia.
    Addington J; Addington D
    Am J Psychiatry; 2005 Jul; 162(7):1387. PubMed ID: 15994732
    [No Abstract]   [Full Text] [Related]  

  • 8. Challenge to atypical antipsychotic drug effect on cognition.
    Carpenter WT; Conley RR
    Am J Psychiatry; 2007 Dec; 164(12):1910-1; author reply 1911-2. PubMed ID: 18056250
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparing symptom response among antipsychotic medications in CATIE.
    Levine SZ; Rabinowitz J; Ascher-Svanum H; Faries DE; Lawson AH
    J Clin Psychopharmacol; 2013 Feb; 33(1):123-6. PubMed ID: 23288232
    [No Abstract]   [Full Text] [Related]  

  • 10. [Schizophrenic syndromes. Diagnosis, development, treatment].
    Carbonnel PA; Robert P; Pringuey D
    Rev Prat; 2000 Jan; 50(2):223-9. PubMed ID: 10737098
    [No Abstract]   [Full Text] [Related]  

  • 11. Overestimating the prevalence of subtherapeutic dosing of atypical antipsychotics.
    Stensland MD; Ascher-Svanum H; Lawson AH; Conley RR
    J Clin Psychiatry; 2009 Aug; 70(8):1189-90; author reply 1190-91. PubMed ID: 19758530
    [No Abstract]   [Full Text] [Related]  

  • 12. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
    Woods SW; Gueorguieva RV; Baker CB; Makuch RW
    Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Subjective well-being under antipsychotic treatment and its meaning for compliance and course of disease].
    Naber D; Lambert M; Karow A
    Psychiatr Prax; 2004 Nov; 31 Suppl 2():S230-2. PubMed ID: 15586315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Combining effectiveness and tolerance].
    Krankenpfl J; 2005; 43(1-3):26-7. PubMed ID: 15912821
    [No Abstract]   [Full Text] [Related]  

  • 15. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
    Patrick DL; Burns T; Morosini P; Gagnon DD; Rothman M; Adriaenssen I
    Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Commentary on the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE).
    Kane JM
    J Clin Psychiatry; 2006 May; 67(5):831-2. PubMed ID: 16841634
    [No Abstract]   [Full Text] [Related]  

  • 17. [CUtLASS 1 - Increasing disillusion about 2nd generation neuroleptics].
    Steinert T
    Psychiatr Prax; 2007 Jul; 34(5):255-7. PubMed ID: 17607643
    [No Abstract]   [Full Text] [Related]  

  • 18. The CATIE study.
    Teich J
    Am J Psychiatry; 2006 Mar; 163(3):554-5; author reply 555-6. PubMed ID: 16513894
    [No Abstract]   [Full Text] [Related]  

  • 19. A critical analysis and discussion of the appropriateness of the schizophrenia consensus remission criteria in clinical pharmaceutical trials.
    Schennach-Wolff R; Möller HJ; Jäger M; Seemüller F; Obermeier M; Messer T; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Maier W; Lemke MR; Rüther E; Klingberg S; Gastpar M; Riedel M
    Pharmacopsychiatry; 2010 Nov; 43(7):245-51. PubMed ID: 20927697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Compliance with medication but not structural MRI measures predict functional outcome in first-episode schizophrenia patients.
    Bachmann S; Bottmer C; Schröder J; Essig M; Magnotta V
    Schizophr Res; 2007 Feb; 90(1-3):355-6. PubMed ID: 17222538
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.